gefitinib + nicotinamide

Gefitinib + nicotinamide is a combination of two small molecules. Gefitinib is an oral tyrosine kinase inhibitor that selectively targets the epidermal growth factor receptor (EGFR) tyrosine kinase, inhibiting its activity and thereby blocking downstream signaling pathways involved in cell proliferation and survival. It is primarily used as first-line therapy for non-small cell lung carcinoma (NSCLC) with specific EGFR mutations[1][4]. Nicotinamide, also known as niacinamide, is a form of vitamin B3 with roles in cellular metabolism and DNA repair; it has been investigated for potential adjunctive effects in cancer therapy but does not have direct antineoplastic activity. The rationale for combining gefitinib with nicotinamide may relate to enhancing anticancer efficacy or modulating resistance mechanisms, though this specific combination does not appear to be an approved or widely studied regimen.